GAP Supply Act

1) What happened and status: HR7528 was introduced by Rep. Carter (R-GA) on February 12, 2026, and referred to the House Energy and Commerce Committee. It has not moved beyond this single referral. The bill amends Section 503B of the FD&C Act to change a timing requirement for outsourcing facilities — giving them 180 calendar days (instead of 'at the time') to continue supplying a drug after it is placed on the FDA shortage list. This is a purely procedural regulatory change. No funds are authorized or appropriated. 2) The money trail: $0. This bill contains no spending authorization, no tax credits, no grants, and no procurement directives. It modifies FDA regulatory compliance timelines only. The mechanism is a reduction in legal risk for compounding pharmacies, not a market-enlarging subsidy. 3) Structural winners and losers: The primary beneficiaries are small-to-mid-sized 503B outsourcing facilities (mostly private companies, not publicly traded). Viatris and other generic injectable manufacturers face marginally increased competition from more authorized compounding during shortages, but the effect is too small and indirect to materially alter earnings. No public pure-play compounding pharmacy tickers exist on US exchanges. 4) Real market data context: is trading at $15.04, up +3.08% over 7 days and +11.32% over 30 days. The stock is near the top of its 52-week range ($8.19–$16.47), but this move is attributable to broader sector rotation and company-specific factors (e.g., patent settlements, generic drug pricing cycles), not this bill. 5) Timeline: The bill is at the earliest possible stage. To become law, it must pass committee markup, pass the House floor, pass the Senate (no companion bill exists), and be signed by the President. Given the 119th Congress is in its second session (2026 is an election year), the window for advancing non-urgent regulatory bills is narrow. Passage probability is low.